The Galeas bladder test is a new, non-invasive DNA-based diagnostic tool that detects bladder cancer by analyzing 23 specific genes in a urine sample. According to reporting from June 2026, the test offers a faster and more accurate alternative to traditional cystoscopy, with early data suggesting it may reduce diagnostic time by 50% for patients presenting with blood in their urine.
How the Galeas Test Outperforms Traditional Cystoscopy
Traditionally, doctors diagnose bladder cancer using cystoscopy, which requires inserting a camera-equipped tube through the urethra into the bladder. According to Jayne Douglas-Moore, a consultant urological surgeon at the University Hospitals of Leicester, this intimate procedure often causes discomfort or embarrassment, leading some patients to decline it entirely. In contrast, the Galeas test requires only a urine sample collected at home.
The diagnostic accuracy of the two methods also differs significantly. An NHS trial involving 964 patients across seven hospitals in England and Scotland during 2024-25 found that the Galeas test correctly identified cancer status in 92% of cases. According to Jeff Bousfield, chief executive of the biotech firm Nonacus, cystoscopy has an accuracy rate of 81%, partly because manual keyhole cameras can struggle to identify bladder cancers of varying sizes and shapes.
Bladder cancer is the 11th most common cancer in the UK, claiming nearly 6,000 lives annually. The Galeas test is designed to catch cases earlier by allowing for testing during a patient’s initial GP visit, rather than waiting for a hospital referral.
Current Rollout and NHS Adoption
University Hospitals of Leicester became the first NHS trust in England to adopt the Galeas test in May 2026. According to Douglas-Moore, the hospital began using the test for patients identified with haematuria via a urine dipstick. At least 16 additional hospitals are expected to adopt the technology by the end of 2026.
The transition is supported by Cancer Research UK, which co-funded initial studies into the technology. Tony Hickson, the organization’s chief business officer, noted that the test aims to make the diagnostic process kinder and quicker. Early results at the Leicester trust indicate that patients are receiving results in 16 days, which exceeds the NHS 28-day faster diagnosis standard for cancer.
Future Trends in Cancer Diagnostics
The development of the Galeas test, led by Prof. Richard Bryan of the University of Birmingham’s bladder cancer research centre and Dr. Doug Ward, signals a broader shift toward non-invasive, molecular-based diagnostics. By leveraging DNA alterations in urine, healthcare systems can potentially reduce the burden on hospital infrastructure while increasing patient compliance.
Prof. Frankie Swords, NHS England’s national medical director, highlighted that the adoption of such technologies reflects a commitment to diagnosing and treating cancer earlier. As the rollout continues, developers hope to further refine the test’s 92% accuracy rate, potentially setting a new standard for urological care across the UK.
Frequently Asked Questions
What is the Galeas bladder test?
It is a non-invasive, DNA-based urine test that identifies bladder cancer by measuring alterations in 23 genes associated with the disease.
Is the test more accurate than a cystoscopy?
According to trial data, the Galeas test demonstrated 92% accuracy compared to the 81% accuracy associated with traditional cystoscopy procedures.
How does this test improve the patient experience?
Patients can provide a urine sample at home instead of undergoing an invasive, uncomfortable, and intimate hospital procedure involving a camera.
How fast are results returned?
Early data from the University Hospitals of Leicester indicates that patients have received results in 16 days, surpassing the NHS 28-day faster diagnosis standard.
Are you interested in how new medical technologies are changing patient care? Subscribe to our health innovation newsletter for the latest updates on NHS breakthroughs and diagnostic advancements.
